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Abstract
Brown adipose tissue (BAT) has well recognized thermogenic properties mediated by uncoupling 
protein 1 (UCP1); more recently, BAT has been demonstrated to modulate cardiovascular risk 
factors. To investigate whether BAT also affects myocardial injury and remodeling, UCP1-
deficient (UCP1−/−) mice, which have dysfunctional BAT, were subjected to catecholamine-
induced cardiomyopathy. At baseline, there were no differences in echocardiographic parameters, 
plasma cardiac troponin I (cTnI) or myocardial fibrosis between wild-type (WT) and UCP1−/− 
mice. Isoproterenol infusion increased cTnI and myocardial fibrosis and induced left ventricular 
(LV) hypertrophy in both WT and UCP1−/− mice. UCP1−/− mice also demonstrated exaggerated 
myocardial injury, fibrosis, and adverse remodeling, as well as decreased survival. Transplantation 
of WT BAT to UCP1−/− mice prevented the isoproterenol-induced cTnI increase and improved 
survival, whereas UCP1−/− BAT transplanted to either UCP1−/− or WT mice had no effect on cTnI 
release. After 3 days of isoproterenol treatment, phosphorylated AKT and ERK were lower in the 
LV's of UCP1−/− mice than in those of WT mice. Activation of BAT was also noted in a model of 
chronic ischemic cardiomyopathy, and was correlated to LV dysfunction. Deficiency in UCP1, 
and accompanying BAT dysfunction, increases cardiomyocyte injury and adverse LV remodeling, 
and decreases survival in a mouse model of catecholamine-induced cardiomyopathy. Myocardial 
injury and decreased survival are rescued by transplantation of functional BAT to UCP1−/− mice, 
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suggesting a systemic cardioprotective role of functional BAT. BAT is also activated in chronic 
ischemic cardiomyopathy.
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1. Introduction
Cardiomyocyte injury leading to cardiac remodeling and subsequent progression to heart 
failure represents a major cause of human morbidity and mortality [1]. To maintain adequate 
cardiac output in the face of decreased ventricular pump function, reflex pathways including 
the sympathetic nervous system are activated, in turn leading to increased catecholamine 
release from the heart and endocrine tissues. This exposure to excess catecholamines 
increases cardiomyocyte death and augments myocardial adverse remodeling [2].
Sympathetic nervous system activation and norepinephrine release [3], concomitant with the 
release of natriuretic peptides [4] occur after myocardial injury and during the development 
of adverse left ventricular (LV) remodeling. Interestingly, these molecules are also major 
contributors to the growth and stimulation of brown adipose tissue (BAT) [5,6]. Brown 
adipose tissue, a relatively sparse brownish-colored adipose tissue well recognized in 
rodents and children, has recently been detected in adult humans [7–9]. Upon activation of 
BAT, the brown adipocytes consume glucose and lipids and convert the energy from free 
fatty acids and glucose oxidation into heat (thermogenesis) [10]. The unique metabolic and 
thermogenic properties of BAT have generated substantial research interest in exploring its 
potential therapeutic applications for obesity and type II diabetes [6,11,12].
The thermogenic capacity of BAT is mediated by the mitochondrial proton transporter 
uncoupling protein 1 (UCP1), which disperses the proton motive force generated by 
oxidative phosphorylation, generating heat as a by-product of this futile cycle [13]. Mice 
deficient in UCP1 (UCP1−/− mice) display impaired activation of BAT in response to cold 
and beta-adrenergic agonists, characterized by a mildly decreased thermogenic capacity 
[14,15], and reduced local blood flow [16].
Recently, several lines of evidence indicated that BAT and related tissues are capable of 
modulating several endocrine and cardiovascular risk factors. BAT activation or 
transplantation normalized both glucose tolerance and insulin resistance in obese or old mice 
[17,18]. Moreover, the beneficial effect on glucose metabolism was also extended to 
humans: in healthy volunteers Chondronikola et al. demonstrated that activated BAT 
increased insulin sensitivity [19]. In addition, perivascular and epicardial adipose tissue 
depots, which share characteristics of BAT [20], are implicated in the modulation of 
atherosclerosis and blood pressure [21].
Although BAT may be activated after myocardial injury and during ventricular remodeling, 
whether this activation has an effect on these processes is unknown. The objectives of the 
present study were to evaluate whether BAT was activated after myocardial injury and 
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whether this activation was cardioprotective. To approach this question we first used a 
model of cardiac injury in which the activation of BAT is well recognized. The model we 
chose, chronic catecholamine (isoproterenol) exposure, leads to cardiac injury and 
cardiomyopathy [22]. Using this model, we compared the cardiac response of wild-type 
(WT) and UCP1−/− mice (with functional and dysfunctional BAT respectively). In a series 
of separate experiments, we then investigated whether BAT was also activated in a clinically 
translatable model of ischemic cardiomyopathy.
2. Material and methods
Additional material and methods are detailed in the Supplemental Data.
2.1. Experimental animals
All animal procedures were conducted in accordance with guidelines published in the Guide 
for the Care and Use of Laboratory Animals (National Research Council, National Academy 
Press, Washington, DC, 1996) and were approved by the Massachusetts General Hospital 
Subcommittee on Research Animal Care. C57Bl6/J WT mice were obtained from Jackson 
Laboratory (Bar Harbor, ME). Whole body UCP1 knockout mice (UCP1−/−) mice, as 
described in Enerbäck et al. [15], were obtained courtesy of Dr. Randall Mynatt (Pennington 
Biomedical Research Center, Baton Rouge, LA) and were bred at Massachusetts General 
Hospital. All mice were housed at thermoneutrality (31 °C) at all times and were studied at 
the age of 12–14 weeks.
2.2. Experimental protocol
All experimental groups are summarized in Fig. 1. Alzet osmotic minipumps (no. 1002; 
Alza Durect Corp., Mountain View, CA, USA) containing isoproterenol (60 mg/kg/d) [23] 
or saline were subcutaneously and dorsally inserted in mice under isoflurane anesthesia. 
Cardiomyocyte injury, gene expression levels and immunoblots were measured 3 days after 
the start of the infusion, and myocardial fibrosis after 14 days. Echocardiographic 
measurements and blood pressure were measured at baseline and after 14 days of saline or 
isoproterenol infusion. Metabolic parameters were obtained at baseline after 16 h of fasting.
Brown adipose tissue transplantation was performed as described previously [18]. Mice 
were allowed to recover for 8 weeks before saline or isoproterenol infusion was started.
Myocardial infarction (MI) was studied in WT mice only and was produced by ligation of 
the left anterior descending coronary artery, as previously described [24]. The mice were 
sacrificed 8 weeks after the procedure.
2.3. Echocardiography
Transthoracic echocardiography was performed as described [25, 26]. LV end-diastolic 
diameter (LVEDD), fractional shortening (FS), anterior wall thickness (AWT) and posterior 
wall thickness (PWT) were obtained from M-mode tracings at the level of the papillary 
muscles. The thickness to radius ratio [27], H/R, was calculated. In the MI model, the LV 
ejection fraction (LVEF) was calculated as previously described [28].
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2.4. Non-invasive blood pressure measurements
Systolic (SBP) and diastolic blood pressure (DBP) were measured non-invasively in awake 
mice by tail-cuff (MC4000MSP, Hatteras Instruments, Inc.) [29].
2.5. Collection and analysis of blood and plasma
Mice were either fed (for cardiomyocyte injury measurement by plasma cardiac troponin I 
(cTnI), fatty acid binding protein 3 (FABP3) and myosin light chain 3 (Myl3) [30]) or fasted 
for 16 h (for glucose, triglyceride and insulin measurements) and anesthetized with 
isoflurane for facial vein puncture. Glucose and insulin tolerance tests (GTT and ITT) were 
performed as previously described [31].
2.6. Tissue analysis
To assess the degree of LV fibrosis, sections were stained with PicroSirius red. The ratio of 
collagen deposition (including perivascular collagen) to total myocardial area was quantified 
(IP Lab Spectrum; Signal Analytics, Vienna, VA) as described [32].
The mRNA expression levels were measured in LV and BAT as previously described [33], 
with specific primer-probe sets for UCP1, UCP2 and UCP3 (Mm00494069_m1, 
Mm00627599_m1, Mm00494077_m1, respectively, Life Technologies) and specific primer 
sets for housekeeping genes RPL13a, ACTB and 18S rRNA (see supplemental data for 
specifics). Antibodies for the immunoblots included P-ERK1/2, ERK1/2, P-AKT and AKT 
(Cell Signaling Technologies, all used at a dilution of 1:1000).
2.7. Statistical analysis
Data are expressed as mean ± SEM. To compare serial echocardiographic parameters and 
blood pressure measurements, we used a two-way ANOVA for repeated measurements. If 
the interaction of time and genotype was significant, unpaired Student's t-tests were used to 
compare parameters between genotypes. For the analysis of changes over time, paired 
Student t-tests were used. To compare cardiac biomarkers and molecular biology 
parameters, one- or two-way ANOVA were used, as appropriate. Linear regression analysis 
was used to determine the correlation coefficient (r2) between BAT activation estimated by 
UCP1 mRNA levels and LVEF after MI. In all experiments, P < 0.05 was considered 
significant. The analyses were performed using Prism 6.0f for Mac (GraphPad Software, La 
Jolla, California, USA, www.graphpad.com).
3. Results
3.1. Adverse LV remodeling after catecholamine exposure is aggravated in UCP1−/− mice
At baseline, LV dimensions and fractional shortening were similar in WT and UCP1−/− mice 
for both genders (Fig. 2 and Table 1 for males, Table S1 for females). Isoproterenol infusion 
for 14 days induced LV concentric hypertrophy (increases in wall thickness, H/R, LV mass) 
in both WT and UCP1−/− mice (Fig. 2A–C, Tables 1, S1), detected both by 
echocardiography and at necropsy. However, isoproterenol induced greater hypertrophy in 
both male and female UCP1−/− mice than in WT mice (Fig. 2A–C, Tables 1, S1). The LV 
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fractional shortening of male UCP1−/− mice decreased after isoproterenol infusion whereas 
it did not in male WT mice (Fig. 2D, Table 1).
Differences in the isoproterenol-induced remodeling between genders were observed. The 
impairment in LV fractional shortening was not detected in female mice (Table S1). In 
addition, after 14 days of isoproterenol infusion a reduction in LV cavity dimensions was 
observed in female UCP1−/− mice whereas LV cavity dimensions did not change in WT 
female mice or in male mice (Tables 1, S1).
Thus, genetic disruption of UCP1 expression predisposes the myocardium to greater adverse 
remodeling in both genders.
3.2. UCP1-deficiency increases fibrosis in catecholamine-induced cardiomyopathy
Analysis of PicroSirius red-stained histological sections revealed virtually no collagen 
deposition in WT (Fig. 2E) or UCP1−/− mice (Fig. 2G) after saline. Fourteen days of 
isoproterenol infusion induced a significant increase of myocardial fibrosis in WT (Fig. 2F) 
and UCP1−/− mice (Fig. 2H). The amount of isoproterenol-induced fibrosis was higher in 
UCP1−/− mice than in WT mice (14 ± 4% vs. 2 ± 1%, p < 0.001, Fig. 1I).
3.3. UCP1-deficiency increases myocardial injury in catecholamine-induced 
cardiomyopathy
Consistent with increased fibrosis, potentially indicating enhanced cardiomyocyte injury and 
death in UCP−/− mice after 14-day isoproterenol treatment, continuous 3-day isoproterenol 
treatment induced a significantly greater increase in plasma cardiac troponin I (cTnI) levels 
in UCP1−/− versus WT mice (6.3 ± 1.5 fold, P < 0.0001; Fig. 3A). Additional plasma 
markers of cardiac injury (FABP3, Fig. 3B and Myl3, Fig. 3C) followed similar patterns, 
indicating a greater degree of cardiomyocyte injury in UCP−/− mice. These data suggest that 
UCP1 limits catecholamine-induced cardiomyocyte injury.
3.4. Decreased survival after catecholamine administration in UCP1−/− mice
The survival of UCP1−/− mice after 14 days of isoproterenol was lower than that of WT 
mice (30/35 (85%) WT and 21/35 (60%) UCP1−/− mice, p < 0.01) (Fig. 3D), suggesting a 
protective effect of UCP1 against isoproterenol-induced death.
3.5. Effects of isoproterenol treatment on gene expression levels of UCP1, UCP2 and UCP3 
in BAT and LV of WT and UCP1−/− mice
Three days of isoproterenol infusion induced a 5-fold increase in UCP1 mRNA levels in 
BAT of WT mice, indicative of BAT activation (Fig. 4A). Expression levels of UCP2 were 
similar in WT and UCP1−/− BAT treated with saline and increased similarly with 3 days of 
isoproterenol (Fig. 4B). The expression levels of UCP3 were comparable between WT and 
UCP1−/− treated with saline, but decreased in UCP1−/− after isoproterenol (Fig. 4C). These 
data indicate that UCP1−/− mice do not seem to compensate the loss of UCP1 by increasing 
the expression of UCP2 or UCP3 in BAT.
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In contrast to the high levels of UCP1 mRNA in WT BAT, UCP1 expression was not 
detected in the LV of WT and UCP1−/− mice, both with saline and with 3 days of 
isoproterenol (Fig. 4A). In the LV, no differences were observed in mRNA expression levels 
of UCP2 in WT and UCP1−/− mice with saline. However, isoproterenol increased the 
expression levels of LV UCP2 mRNA in UCP1−/− mice (Fig. 4B). UCP3 levels were 
comparable in the LV of WT and UCP1−/− treated with saline, and decreased similarly with 
isoproterenol (Fig. 4C). These data suggest that the LV does not express UCP1 mRNA and 
that the only difference between WT and UCP1−/− animals is an increase in the gene 
expression levels of UCP2 in UCP1−/− mice after isoproterenol.
3.6. The effect of isoproterenol on blood pressure is similar in WT and UCP1−/− mice
Wild-type and UCP1−/− mice had a similar BP at baseline. Isoproterenol-infusion for 14 
days induced a similar increase in BP in both genotypes (Figure S1). These findings suggest 
that the differences in cardiac remodeling are not caused by differences in blood pressure.
3.7. Metabolic parameters of WT and UCP1−/− mice at the age of 12–16 weeks
There were no differences between WT and UCP1−/− mice in body weight (Fig. 4A), plasma 
glucose (Fig. 5B), insulin (Fig. 5C), and triglycerides (Fig. 5D) levels in mice fasted for 16 
h. However UCP1−/− mice demonstrated mildly impaired glucose tolerance after a bolus 
glucose injection and glucose recovery after insulin injection (Fig. 5E–F). Therefore, mild 
metabolic abnormalities are noted in the UCP1−/− mice.
3.8. Transplantation of functional BAT in UCP1−/− mice limits cardiomyocyte injury and 
reduces mortality in catecholamine-induced cardiomyopathy
To determine whether the presence of functional BAT reverses the increased cardiac injury 
observed in UCP1−/− mice, BAT transplantations were performed. At 8 weeks, glucose 
tolerance was lower in UCP1−/− mice receiving UCP1−/− BAT transplants compared to WT 
mice receiving UCP1−/− BAT transplants, and increased by transplantation of WT BAT to 
UCP1−/− mice (Fig. 6A). These results demonstrate that transplantation of functional BAT 
into the visceral cavity of UCP1−/− mice improves whole-body glucose homeostasis.
Transplanted WT and UCP1−/− mice were infused continuously with isoproterenol or saline 
for 3 days and then plasma cTnI was measured. cTnI levels were markedly increased in the 
UCP1−/− mice transplanted with UCP1−/− BAT compared to WT mice transplanted with 
UCP1−/− BAT and UCP1−/− mice transplanted with WT BAT (Fig. 6B). The levels of cTnI 
in the mice transplanted with UCP1−/− BAT were similar to those of non-transplanted mice 
of the same strain. Importantly, no difference in cTnI levels was observed between UCP1−/− 
mice transplanted with WT BAT and WT mice transplanted with UCP1−/− BAT (Fig. 5B), 
indicating that transplantation of functional WT BAT protects against catecholamine-
induced cardiomyocyte injury in vivo. Interestingly, mortality following isoproterenol stress 
was higher in the UCP1−/− mice transplanted with UCP1−/− BAT compared to all the other 
transplantation groups (Fig. 6C). These findings suggest that BAT remotely mediates 
cardioprotection and protects against the isoproterenol-stress induced mortality.
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3.9. UCP1-deficiency limits the activation of cardioprotective signaling pathways during 
catecholamine exposure
Western blots revealed that WT and UCP1−/− mice have a similar degree of AKT (Fig. 7A) 
and ERK1/2 (Fig. 7B) phosphorylation in the LV after saline. After 3 days of isoproterenol 
infusion, phosphorylation of AKT (Fig. 7A) was unchanged in the WT and decreased in the 
UCP1−/− mice compared to saline. In contrast, isoproterenol treatment was associated with 
an increase in phosphorylation of ERK1/2 in WT but not UCP1−/− mice (Fig. 7B). Thus, 
cardioprotective signaling mechanisms through AKT might be attenuated in UCP1−/− mice 
while cardioprotective signaling through ERK1/2 are not activated in UCP1−/− mice after 
catecholamine-induced cardiomyocyte injury.
3.10. BAT is activated in ischemic cardiomyopathy
BAT gene expression levels of UCP1 in WT mice were higher eight weeks after myocardial 
infarction (MI) induced by left coronary artery ligation, than 8 weeks after sham 
intervention (Fig. 8A). At the same time point, BAT weight was greater in mice after MI 
than after sham operation (203 ± 22 mg vs. 131 ± 7 mg, p = 0.02). Additionally, the 
expression level of UCP1 was correlated to the degree of cardiac dysfunction, ascertained by 
echocardiographic LVEF (Fig. 8B) (r2 = 0.4052, p < 0.001). These data demonstrate that 
BAT is activated after MI, and that the activation is related to the degree of LV dysfunction.
4. Discussion
The present study provides the first experimental evidence that functional BAT remotely 
protects against cardiomyocyte injury and maladaptive remodeling in vivo. Although 
previous studies have suggested a potential role for BAT and BAT-secreted factors in 
regulating cardiovascular risk factors [6,17] no study has addressed the ability of BAT to 
protect cardiomyocytes.
Our results suggest that the absence of UCP1 is associated with increased cardiomyocyte 
injury and cardiac remodeling in a model of catecholamine-induced cardiomyopathy. The 
detection of higher levels of cTnI, an early marker of cardiomyocyte injury [30], in the 
plasma of UCP1−/− mice compared to WT mice, and the reversal of this difference by WT 
BAT transplantation, suggest that the presence of functional BAT protects cardiomyocytes 
against catecholamine-induced injury. A cardioprotective local effect of cardiac UCP1 
expressing cells is highly unlikely as QPCR analysis using highly sensitive and specific 
taqman probes did not reveal any UCP1 expression in the mouse LV, a finding that confirms 
previous analysis in rodents [34]. Uncoupling proteins 2 and 3 are expressed in the heart and 
UCP2 has been shown to decrease cardiomyocyte death [35]. However, a decrease in 
cardiac UCP2 in UCP1−/− mice that would increase cardiomyocyte injury after isoproterenol 
is unlikely based on the increase in mRNA observed in this strain. An increase in UCP3 has 
recently been implicated in the decreased efficiency of diabetic hearts post ischemia–
reperfusion [36]; such an increase in UCP1−/− mice is also unlikely as UCP3 mRNA is 
robustly decreased after isoproterenol infusion in this strain.
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UCP1−/− mice were found to have a substantial increase in collagen deposition compared to 
WT mice after isoproterenol. In isoproterenol infusion models, myocardial fibrosis has been 
closely related to the amount of myocardial necrosis [37]. Thus, the increased fibrosis is 
most likely due to the increased cardiomyocyte injury. Finally, a more pronounced 
concentric hypertrophic remodeling of the LV following isoproterenol infusion was 
observed in UCP1−/− mice; this effect could be due to the absence of a direct 
antihypertrophic effect of BAT or to a secondary response to the increased fibrosis. In male 
UCP1−/− mice, the maladaptive remodeling was accompanied by a decrease in LV systolic 
function, whereas in female UCP1−/− mice, increased concentric hypertrophy was noted. 
Similar gender differences in LV remodeling have been described previously in murine 
[38,39] and human [40] models of MI and pressure-overload and may be due to the role of 
estrogens.
The survival of UCP1−/− mice after isoproterenol infusion was lower than that of WT mice. 
The deaths mostly occurred within the first 5 days after the start of the infusion. Based on 
our echocardiographic data, it is unlikely that the observed deaths are due to heart failure, as 
the drop in LVEF was modest. Similarly, we did not observe a marked increase in the blood 
pressure of UCP1−/− mice that could explain an increase in mortality. One potential 
mechanism explaining the decreased survival of UCP1−/− mice could involve larger clusters 
of necrotic cells that would provide more arrhythmogenic foci in the UCP1−/− mice.
Isoproterenol infusion for three days was associated with an increase in the phosphorylation 
of ERK1/2 in WT mice, but not in UCP1−/− mice. Additionally, the phosphorylation of AKT 
was decreased in UCP1−/− mice after isoproterenol whereas it was unchanged in WT. Both 
ERK1/2 and AKT have been implicated as cardioprotective pathways in ischemia–
reperfusion injury [41,42]. Activation of ERK1/2 decreases the opening of the mitochondrial 
permeability transition pore [43], and inhibits apoptotic pathways in cardiomyocytes [44]. 
The Pi3K–AKT pathway has long been recognized as one of the most potent pro-survival 
pathways in the heart and activates potent anti-apoptotic signaling pathways in 
cardiomyocytes [42,45]. Intrinsic states of AKT phosphorylation have been shown to 
determine cell fate after different myocardial insults. A deficiency in the phosphorylation of 
AKT, as seen in our data, is generally detrimental for cardiomyocyte survival [45].
Our data indicate that BAT exerts a systemic action that results in a cardioprotective 
mechanism. Recently, the endocrine potential of BAT has generated research interest [46]. 
Several signaling molecules with endocrine properties are released by BAT, especially when 
activated [18,47–49]. The endocrine properties of BAT are relevant in physiological 
processes. For example, experimental BAT transplantation has been shown to improve 
glucose tolerance and insulin sensitivity, through an increase in interleukin 6 [18]. The heart 
is a potential target of adipokines synthetized in BAT such as FGF21; FGF21 demonstrated 
cardiac antihypertrophic effects [50], and a recent study reported cardioprotective effects of 
FGF21 in a mouse model of experimental MI [51]. Therefore, it is possible that BAT 
secretes an adipokine with direct cardioprotective signaling properties in the heart. It is less 
likely that BAT from UCP1−/− mice would secrete a cardiotoxic adipokine since the levels 
of cTnI from WT and UCP1−/− mice transplanted with UCP1−/− BAT were similar to those 
of untransplanted mice before and after isoproterenol.
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Alternatively, BAT activity is correlated to overall improvements in metabolism and hence, 
improved glucose and insulin handling [17, 18]. Although the metabolic abnormalities 
detected in the UCP1−/− mice in our study were modest, the mild glucose intolerance may 
still negatively impact cardioprotection. Interestingly, however, several studies have noted 
that diabetes decreased rather than increased the amount of necrosis in catecholamine-
induced injury, maybe due to desensitization to the catecholamine effects [52–54]. Of note, 
one limitation of the present study is that the functional consequences of the limitation of 
cardiac injury by BAT transplantation were not investigated.
Brown adipose tissue is activated and cardioprotective in a model of catecholamine-induced 
cardiomyopathy that attempts to reproduce the high levels of catecholamines present in heart 
failure. Such high levels of catecholamines, however, are infrequent. It is therefore 
noteworthy that BAT is also activated after MI and that the activation was correlated to the 
degree of LV dysfunction. Whether BAT is cardioprotective after MI or in other models of 
heart failure should be further studied.
In humans, Chondronikola et al. [19] have recently demonstrated that the presence of 
functional BAT does improve insulin sensitivity. Brown adipose tissue or brown adipocyte 
transplantation has been suggested as a potential therapy of obesity [11] and has become 
more attainable as the culture of human brown adipocytes has been achieved [7]. Thus, it is 
conceivable, if BAT shows further promises as a cardioprotective tissue, that it may be 
applied in humans.
In conclusion, in catecholamine-induced cardiomyopathy, activated BAT decreases 
myocardial injury, fibrosis, and LV adverse remodeling through a systemic effect. This 
cardioprotective effect could be due to secreted substances (so-called batokines) or occur 
through systemic improvements in metabolism. If such a cardioprotective effect can be 
extended to other models of heart failure, BAT activation or transplantation may show 
promise as novel therapeutic avenues.
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LV left ventricle
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H/R wall thickness/LV radius
LVMI LV mass index
cTnI cardiac troponin I
MI myocardial infarct
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PWT posterior wall thickness
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AWT anterior wall thickness
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DBP diastolic blood pressure
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ITT insulin tolerance test
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MYL3 myosin light chain 3
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Fig. 1. 
Flow chart of experimental procedures.
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Fig. 2. 
Effect of 14 days of isoproterenol infusion on echocardiographic and pathologic parameters 
in male WT and UCP1−/− mice. The UCP1−/− mice developed more LV hypertrophy and 
fibrosis than WT mice and decreased LV fractional shortening after isoproterenol. Panel A: 
Posterior wall thickness (PWT) measured with echocardiography. Panel B: 
Echocardiographically-derived thickness/radius ratio (H/R). Panel C: Ratio of LV mass 
measured at necropsy to bodyweight (LVW/BW). Panel D: Echocardiographically-derived 
fractional shortening (FS). (Echocardiographic data acquired in WT SAL N = 6, WT ISO N 
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= 8, KO SAL N = 11, KO ISO N = 8) Panels E, F, G, H, I: Myocardial fibrosis detected by 
PicroSirius staining. Representative slices in a WT mouse (E) and UCP1−/− mouse (G) after 
14 days of saline infusion and in a WT mouse (F) and UCP1−/− mouse (H) after 14 days of 
isoproterenol infusion. Panel I: Quantification of myocardial fibrosis in WT and UCP1−/− 
mice, after 14 days of saline or isoproterenol infusion (WT SAL N = 6, WT ISO N = 8, KO 
SAL N = 5, KO ISO N = 5). *: p < 0.05; **: p < 0.01; ***: p < 0.001 vs. sham (saline 
infusion) of the same strain at 14 days; $$: p < 0.01; $$$: p < 0.001 vs. baseline (D0) in the 
same strain; #: p < 0.05; ###: p < 0.001 vs. isoproterenol in WT mice. WT: wild-type; KO: 
UCP1−/− mice; D0: baseline; D14: 14 days of isoproterenol; SAL: saline infusion; ISO: 
isoproterenol infusion.
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Fig. 3. 
Markers of myocardial injury in WT and UCP1−/− mice at 3 days and survival of WT and 
UCP1−/− mice with saline or isoproterenol infusion after 14 days. Panel A–C: Cardiac 
troponin I (cTnI, Panel A), fatty acid binding protein 3 (FABP3, Panel B), myosin light 
chain 3 (Myl3, Panel C) were measured in EDTA plasma after 3 days of isoproterenol. Both 
cTnI and Myl3 were higher in WT and UCP1−/− mice, however, the increase was greater in 
UCP1−/−mice. FABP3 only increased in UCP1−/− mice. (WT SAL N = 12, WT ISO N = 12, 
KO SAL N = 11, KO ISO N = 10). Panel D: Kaplan–Meier plot of survival during 14 days 
of follow-up in WT and UCP1−/− mice after saline or isoproterenol infusion (WT SAL N = 
25, WT ISO N = 35, KO SAL N = 25, KO ISO N = 35). **: p < 0.01; ****: p < 0.0001 vs. 
saline infusion of the same strain; ##: p < 0.01; ###: p < 0.001 vs. isoproterenol in WT mice. 
WT: wild-type; KO: UCP1−/− mice; SAL: saline infusion; ISO: isoproterenol infusion.
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Fig. 4. 
Gene expression levels of uncoupling proteins 1 (Panel A), 2 (Panel B) and 3 (Panel C) in 
the brown adipose tissue and left ventricle of WT and UCP1−/− mice, after 3 days of saline 
or isoproterenol infusion. Panel A: UCP1 expression increased in WT BAT after 
isoproterenol and was not detected in the LV of WT mice. Panel B–C: No compensatory 
increase in the expression levels of UCP2 and 3 in BAT was noted in UCP1−/− mice. Panel 
B: Levels of UCP2 in the LV were similar between WT and UCP1−/− mice at baseline but in 
UCP1−/− mice UCP2 in the LV was increased by isoproterenol. Panel C: The changes in 
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UCP3 in the LV induced by isoproterenol were similar between WT and UCP1−/− mice. (N 
= 6 for all groups). *: p < 0.05; **: p < 0.01; ***: p < 0.001 vs. saline infusion of the same 
strain at 3 days; #: p < 0.05; ###: p < 0.001 vs. same condition (saline or isoproterenol) in 
WT mice. WT: wild-type; KO: UCP1−/− mice; SAL: saline infusion; ISO: isoproterenol 
infusion; BAT: brown adipose tissue; LV: left ventricle.
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Fig. 5. 
Body weight and metabolic parameters in WT and UCP1−/− mice. Panel A: Body weight of 
WT and UCP1−/− mice (WT N = 12, KO N = 14). Panel B–D: Plasma levels of glucose 
(Panel B) (WTN = 12, KON = 14), insulin (Panel C) (WTN = 8, KO N = 6) and 
triglycerides (Panel D) (WTN = 10, KON = 8) in mice fasted for 16 h were similar in the 
WT and UCP1−/− mice. Panel E–F: Glucose tolerance test (WTN = 12, KO N = 14). (Panel 
E) and insulin tolerance test (WT N = 8, KO N = 6). (Panel F) in WT and UCP1−/− mice. 
The UCP1−/− mice were glucose-intolerant, however, were not insulin resistant compared to 
WT mice. **: p < 0.01; ***: p < 0.001 vs. WT at the same time point. TG: triglycerides; 
WT: wild-type; KO: UCP1−/− mice; GTT: glucose tolerance test; ITT: insulin tolerance test.
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Fig. 6. 
Effects of the transplantation of brown adipose tissue (BAT) on the glucose tolerance (Panel 
A), and plasma cardiac troponin I levels (Panel B) and survival (Panel C) after isoproterenol 
infusion. Panel A–B: The transplantation of WTBAT attenuated the glucose intolerance in 
UCP1−/− mice 8 weeks post-transplantation (Panel A) (UCP1−/− BAT to WTN = 10, WT 
BAT to UCP1−/− N = 10, UCP1−/− BAT to UCP1−/− N = 10) and prevented the increased 
plasma cardiac troponin I level detected 3 days after isoproterenol infusion (Panel B) 
(UCP1−/− BAT to WT: SAL N = 3, ISO N = 6; WT BAT to UCP1−/−: SAL N = 3, ISO N = 
3; UCP1−/− BAT to UCP1−/− SAL N = 3, ISO N = 3). Panel C: Mortality was higher in 
UCP1−/− mice transplanted with UCP1−/− BAT after 14 days of isoproterenol infusion. 
(SAL groups N = 5, ISO groups N = 6) *: p < 0.05; **: p < 0.01; ***: p < 0.001 vs. baseline 
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of the same group; #: p < 0.05; ###: p < 0.001 vs. WT to KO at the same time point; $$: p < 
0.01 vs. KO to WT at the same time point; ††: p < 0.01; †††: p < 0.001 vs. KO to WT at the 
same time point: wild-type; KO: UCP1−/− mice; SAL: saline infusion; ISO: isoproterenol 
infusion; KO to WT: KO BAT to WT mouse; WT to KO: WT BAT to KO mouse; KO to 
KO: KO BAT to KO mouse. WT: wild-type; KO: UCP1−/− mice.
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Fig. 7. 
Effect of isoproterenol infusion on the phosphorylation of AKT and ERK. Panel A–B: 
Representative immunoblots and quantification of P-AKT on Ser473 and total AKT (Panel 
A) and P-ERK1/2 on Thr202/Tyr204 and Thr185/Tyr187, respectively, and total ERK 1/2 
(Panel B) on LV homogenates of WT and KO mice after 3 days of saline or isoproterenol 
infusion. Densitometry is presented as an average of 3 technical repeats, with 4 biological 
repeats per group. *: p < 0.05; **: p < 0.01 vs. saline of the same group; #: p < 0.05 vs. 
isoproterenol in WT mice. WT: wild-type; KO: UCP1−/− mice.
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Fig. 8. 
Activation of brown adipose tissue (BAT) in heart failure. Panel A: Activation of BAT, 
assessed by the gene expression level of UCP1, was noted 8 weeks after myocardial 
infarction and was correlated to the degree of LV dysfunction. Gene expression levels of 
UCP1 in WT mice, either sham-operated or subjected to left anterior descending coronary 
artery ligation (SHAM N = 11; MI N = 13). Panel B: Correlation between UCP1 gene 
expression levels and LV ejection fraction. The straight line represents the correlation, the 
dashed line the 95% confidence interval of the correlation. MI: myocardial infarction, 
LVEF: left ventricular ejection fraction. *: p < 0.05 vs. SHAM.
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; L
V
ES
D
: L
V
 e
nd
-s
ys
to
lic
 in
te
rn
al
 d
ia
m
et
er
; H
R:
 h
ea
rt 
ra
te
, L
V
M
I: 
LV
 m
as
s i
nd
ex
 (e
ch
oc
ard
iog
rap
hy
), H
/R
: th
ick
ne
ss 
on
 ra
diu
s r
ati
o, 
BW
: b
od
y w
eig
ht.
$ : 
p 
< 
0.
05
 v
s. 
sa
m
e t
re
at
m
en
t a
nd
 sa
m
e g
ro
up
 o
n 
da
y 
0,
*
: 
p 
< 
0.
05
 v
s. 
sa
lin
e t
re
at
m
en
t o
f t
he
 sa
m
e s
tra
in
 o
n 
sa
m
e d
ay
,
# :
 p
 <
 0
.0
5 
vs
. s
am
e t
re
at
m
en
t o
n 
sa
m
e d
ay
 in
 W
T 
IS
O
.
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